

References:

1. https://care.diabetesjournals.org/content/43/Supplement_1
2. Johnson et al. Diabetes Care 2002
3. Hong J et al. Diabetes Care. 2013;36(5):1304-1311
4. <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf>
5. New Engl J Med 2016; 375:311-322 July 28, 2016
6. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
7. Kristensen SL et al. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785
8. Husain et al. N Engl J Med 2019
9. Tahrani et al. Diabetes Ther. 2010 Dec;1 (2):45-56
10. Zinman et al. N Engl J Med 2015. 373; 22
11. Wanner et al. JASN November 2018
12. Neal B. et al N Engl J Med. 2017; 377(7):644
13. Wiviott et al. NEJM 2019
14. Zelniker et al. Lancet Jan. 2019
15. Perkovic et al. Credence Group. NEJM April 2019
16. Heerspink et al. N Engl J Med. September 24th 2020
17. Verma and McMurray. Diabetologia 2018
18. [https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin#:~:text=8%2D26%2D2020%20FDA%20Drug,%2C%20Invokamet%20XR\)%20prescribing%20information](https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin#:~:text=8%2D26%2D2020%20FDA%20Drug,%2C%20Invokamet%20XR)%20prescribing%20information)
19. Riddle MC. J Clin Endocrinol Metab 2003
20. DeFronzo, R. Banting Lecture, Diabetes vol. 58 2009
21. Scirica BM et al. SAVOR-TIMI 53. N Engl J Med 2013; 369: 1317-1326
22. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes>

23. Bischoff H. "Effect of acarbose on diabetic late complications and risk factors – new animal experimental results". *Akt Endokr Stoffw.* 1991;12:25–32